Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

Background The RTS, S/AS01 vaccine targets the circumsporozoite protein of Plasmodium
falciparum and has partial protective efficacy against clinical and severe malaria disease in …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

RTS, S is an advanced malaria vaccine candidate and confers significant protection against
Plasmodium falciparum infection in humans. Little is known about the molecular …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background Over the past decade malaria intervention coverage has been scaled up across
Africa. However, it remains unclear what overall reduction in transmission is achievable …

Background An effective vaccine for malaria is urgently needed. Naturally acquired immunity
to malaria develops slowly, and induction of protection in humans can be achieved …

Abs are central to malaria immunity, which is only acquired after years of exposure to
Plasmodium falciparum (Pf). Despite the enormous worldwide burden of malaria, the targets …